CTOs on the Move

Zymergen

www.zymergen.com

 
Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zymergen.com
  • 5980 Horton Street Suite 105
    Emeryville, CA USA 94608
  • Phone: 415.801.8073

Executives

Name Title Contact Details
Dmitriy Ryaboy
Chief Technology Officer Profile

Funding

Zymergen raised $44M on 06/16/2015
Zymergen raised $130M on 10/11/2016
Zymergen raised $400M on 12/13/2018
Zymergen raised $300M on 09/08/2020

Similar Companies

Eiger BioPharmaceuticals

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger`s pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.

Seed Health

Seed Health is a microbial sciences company pioneering applications of microbes for human and planetary health. In collaboration with leading academic researchers, we advance breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics, consumer health innovations and environmental solutions.

Cellestis Limited

Cellestis Limited is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aptinyx

Aptinyx Inc. (formerly Naurex Inc.) is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism that modulates NMDA receptors, resulting in drugs that are both highly effective and well tolerated. This mechanism has applicability across a number of brain and nervous system disorders. Aptinyx is rapidly advancing promising drug candidates into clinical development for indications with high unmet medical need.

EV Biologics

EV Biologics is a biotechnology company that is developing extracellular vesicles (EVs) to create diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions.